NL-OMON36770
Recruiting
Phase 4
ong term prospective observational cohort study of the safety and efficacy of certolizumab pegol in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profile - Certolizumab pegol in rheumatoid arthritis
Jan van Breemen Instituut0 sites200 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- inflammatory rheumatic disease
- Sponsor
- Jan van Breemen Instituut
- Enrollment
- 200
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients with rheumatoid arthritis in whom certolizumab pegol treatment is started.
- •written informed consent
Exclusion Criteria
- •contraindications against certolizumab pegol treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
ong term prospective observational cohort study of the safety and efficacy of golimumab in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profileinflammatory rheumatic disease1000381610023213NL-OMON36406Jan van Breemen Instituut200
Recruiting
Phase 4
ong term prospective observational cohort study on the safety and efficacy of abatacept subcutaneus in the daily clinical practice of rheumatoid arthritisInflammatory rheumatic disease10023213NL-OMON39013Jan van Breemen Instituut100
Completed
Not Applicable
ong term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribineG35.9DRKS00015267Merck KGaA1,115
Not yet recruiting
Not Applicable
Rate of multidrug resistance to antimicrobial drugs in paediatric neurointensive care patientsHealth Condition 1: Z163- Resistance to other antimicrobialdrugsCTRI/2019/10/021721All India institute of medical sciences
Completed
Not Applicable
Venous thromboembolism in care homesISRCTN80889792niversity of Birmingham (UK)1,000